european central bank digital currency- Top People searches

Port hedland's iron ore exports increased to 48.755 million tons in November.Dalian Shengya had a daily limit in the afternoon, and its share price hit a record high. Since November, its cumulative increase has exceeded 150%.Vista Jiajie: The development of cloud computing and digitalization in Asia-Pacific IT distribution is accelerating. According to the research report of CLSA, Vista Jiajie, as the eighth largest IT distributor in the world and the second largest IT distributor in China, has benefited from the rapid growth of cloud computing and the digitalization development in Southeast Asia, and has a good market position. The company occupies a dominant position in the ICT industry in the Asia-Pacific region, especially in Southeast Asia and China, with obvious demographic advantages and huge growth potential. Vista Jiajie is Starlink's preferred partner in ASEAN. The global cloud computing market is expected to grow at a compound annual growth rate of 18.6% from 2023 to 2027. Vista Jiajie has an optimistic prospect in the fields of cloud computing and artificial intelligence.

IDC: The global market for sweeping robots continued to grow in the third quarter. According to IDC's Quarterly Tracking Report on the Global Smart Home Equipment Market, the third quarter of 2024, the global market for intelligent sweeping robots shipped 5.014 million units in the third quarter, up 11.1% year-on-year. Among them, the domestic market was boosted by the trade-in of old models at the end of September, with 1.321 million units shipped, up by 17% year-on-year, and the efforts of most provinces were around 20%, which significantly stimulated the shipment of high-end models, and this trend also continued to this year's "Double Eleven". The proportion of overseas sales of China manufacturers continues to increase, and the competition of high-end all-around models in European and American markets is still fierce.CMB International: Upgraded the target price of WuXi Bio to HK$ 22.88, optimistic about the company's valuation and performance repair. CMB International published a report, predicting that the US Biosafety Act will fail with high probability, which will help WuXi Bio to achieve continuous performance growth in a relatively stable business environment. With the recovery of global biomedical financing, we are optimistic about the company's valuation and performance repair. According to the report, the NDAA in FY 2025 does not include the Biosafety Act, and the legislation of the Biosafety Act failed with high probability. On December 7, the US Senate and the House Armed Services Committee announced the National Defense Authorization Act (NDAA) for fiscal year 2025, which was finally negotiated by the committees of the two houses. The Biosafety Act was not included in the amendment of NDAA in FY 2025, which means that the Biosafety Act failed to pass the legislative path of joining NDAA. The Biosafety Act can still promote separate legislation, but considering that the window of the current US Congress session is less than two weeks, the Bank believes that the success rate of separate legislation is extremely low. CMB International maintained the "Buy" rating of Yaoming Bio, and its target price rose from HK$ 13.58 to HK$ 22.88. It is estimated that the company's revenue will increase by 7.1%/12.4%/ 13.9% from 2024 to 2026, and its adjusted net profit will increase by 0.8%/11.1%/13.4% respectively.Joy City's daily limit The fourth Joy City in Beijing is about to open, and Joy City (000031.SZ) has raised its daily limit to a new high price in 4 yuan for 15 months, with a total market value of 17.1 billion yuan. According to the news, Haidian Joy City, the fourth Joy City in Beijing, will open on December 21st. At present, the second installation of many brands has come to an end, and the merchants in the venue have entered intensive preparations for opening.

New Beiyang (Thailand) Company opened. According to the news of New Beiyang, on December 12th, the launching ceremony of New Beiyang (Thailand) Company was held in chonburi province, Thailand. This was the first factory established by New Beiyang overseas, which marked another major breakthrough in the company's internationalization strategy and laid a solid foundation for the company's future internationalization development. The park leased by New Beiyang (Thailand) Company covers an area of more than 5,500 square meters in the first phase. At present, the special printing and scanning product line built in the factory has been successfully put into production and is ready to start mass delivery. In the future, the company will continue to expand the production and delivery of some smart equipment products in Thai factories.The concept of unmanned driving changed partially. Both Haida and SAIC have daily limit, while the concept of unmanned driving changed partially. Both Zhonghaida and SAIC have daily limit, and Gaoxinxing, Huati Technology, Yutong Heavy Industry and Jinlong Automobile have followed suit.CMB International: Upgraded the target price of WuXi Bio to HK$ 22.88, optimistic about the company's valuation and performance repair. CMB International published a report, predicting that the US Biosafety Act will fail with high probability, which will help WuXi Bio to achieve continuous performance growth in a relatively stable business environment. With the recovery of global biomedical financing, we are optimistic about the company's valuation and performance repair. According to the report, the NDAA in FY 2025 does not include the Biosafety Act, and the legislation of the Biosafety Act failed with high probability. On December 7, the US Senate and the House Armed Services Committee announced the National Defense Authorization Act (NDAA) for fiscal year 2025, which was finally negotiated by the committees of the two houses. The Biosafety Act was not included in the amendment of NDAA in FY 2025, which means that the Biosafety Act failed to pass the legislative path of joining NDAA. The Biosafety Act can still promote separate legislation, but considering that the window of the current US Congress session is less than two weeks, the Bank believes that the success rate of separate legislation is extremely low. CMB International maintained the "Buy" rating of Yaoming Bio, and its target price rose from HK$ 13.58 to HK$ 22.88. It is estimated that the company's revenue will increase by 7.1%/12.4%/ 13.9% from 2024 to 2026, and its adjusted net profit will increase by 0.8%/11.1%/13.4% respectively.